Sinclair Pharma Limited et al. v. HydraFacial LLC

IPR2025-00145

Sinclair Pharma has filed an IPR petition challenging HydraFacial's skin‑treatment patent (US 11,865,287). The petition alleges obviousness over four prior‑art references and requests cancellation of 41 claims. The Board has not yet ruled on institution.

Jurisdiction
US PTAB
Case Number
IPR2025-00145
Decision Date
25 November 2024
Filing Date
25 November 2024

Detailed Summary

In IPR2025-00145, Sinclair Pharma Limited and affiliates petition the PTAB to institute an Inter Partes Review of HydraFacial LLC’s U.S. Patent No. 11,865,287, which claims a skin‑treatment system with a console, multiple fluid containers, a handpiece, and a vacuum source. The petitioner contends that the invention is unpatentable under 35 U.S.C. §103 by combining teachings from the Karasiuk, Palmer, Greenberg, and Trueba references, arguing that the examiner never considered these combinations. The petition seeks cancellation of all 41 challenged claims and argues that discretionary denial under §325(d) is not warranted. No Board decision has been issued yet; the proceeding remains at the petition stage.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Sinclair Pharma Limited et al. vs HydraFacial LLC is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentIPR2024-00543

TESLA, INC.vsiQar Inc.

Tesla successfully instituted an IPR against iQar Inc.'s patent covering power management/cruise control systems, asserting obviousness over all challenged claims (1-20). The Board found a reasonable likelihood of prevailing on the grounds that combining prior art references like Hongo and Obradovich renders the claimed technology obvious.

patentIPR2024-01191

Wiz, Inc.vsOrca Security Ltd.

Wiz challenged Orca Security Ltd.'s cloud security patents, arguing that the claimed vulnerability scanning methods are obvious combinations of known techniques. The petitioner asserts that merging Veselov's snapshot scanning with Basavapatna's risk assessment renders the invention predictable.

patentIPR2024-01121

AT&T Services Inc. et al.vsASUS Technology Licensing Inc.

Multiple wireless carriers, including AT&T, T-Mobile, and Verizon, have filed an IPR petition challenging the validity of patents held by ASUS Technology Licensing Inc. and Celerity IP, LLC. The core dispute centers on claims related to beamforming control signaling in massive MIMO systems. Petitioners assert that the claimed novelty is anticipated or rendered obvious by existing prior art.

patentIPR2024-00561

Juniper Networks, Inc.vsMonarch Networking Solutions LLC

Juniper Networks successfully petitioned to institute IPR against Monarch Networking Solutions LLC regarding packet switching claims (Claims 1 and 6). The Board found sufficient evidence of obviousness over combinations of prior art references, including Wainner/Bocci and Kamite/Bocci.

patentIPR2024-00372

Samsung Electronics Co., Ltd. et al.vsAdvanced Coding Technologies, LLC

Samsung and video‑codec startup Advanced Coding Technologies have settled their dispute over a moving‑picture encoding patent, filing a joint motion to terminate the inter partes review.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call